» Articles » PMID: 19890902

Prognostic Factors in Pulmonary Metastasized High-grade Osteosarcoma

Overview
Date 2009 Nov 6
PMID 19890902
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Resection of pulmonary metastases has previously been reported to improve outcome in high-grade osteosarcoma (OS) patients. Factors influencing survival in OS patients with pulmonary metastases are important for clinical decision making.

Methods: All 88 OS patients with pulmonary metastases either at diagnosis or during follow-up treated at the Leiden University Medical Center between January 1, 1990 and January 1, 2008 under the age of 40 were included in this study, including 79 cases of conventional, 8 cases of telangiectatic and 1 case of small cell OS.

Results: In total, 56 of 88 patients with pulmonary metastases were treated by metastasectomy. Resectability of pulmonary metastases was the main prognostic factor. In patients with primary non-metastatic OS, a longer relapse free interval to pulmonary metastases was significantly associated with better survival (P = 0.02). Independent risk factors determining worse survival after metastasectomy in multivariate analysis were male sex (P = 0.05), higher number of pulmonary nodules (P = 0.03), and non-necrotic metastases (P = 0.04). Whether surgery for recurrent pulmonary metastases was performed did not influence survival. Histological subtype of the primary tumor, histological response in the primary tumor after neo-adjuvant chemotherapy, occurrence of local relapse, local resection or amputation of the primary tumor and age at diagnosis did not influence outcome.

Conclusion: This cohort of patients with detailed follow-up data enabled us to identify important risk factors determining survival in OS patients with pulmonary metastases. We demonstrate that after repeated metastasectomies, a subset of patients can be cured.

Citing Articles

Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF.

Mustokoweni S, Mahyudin F, Setiawati R, Nugrahenny D, Hidayat M, Kalim H Virchows Arch. 2024; 484(6):925-937.

PMID: 38748263 PMC: 11186924. DOI: 10.1007/s00428-024-03801-z.


Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group.

Mettmann V, Blattmann C, Friedel G, Harrabi S, von Kalle T, Kager L Cancers (Basel). 2024; 16(2).

PMID: 38254767 PMC: 10813782. DOI: 10.3390/cancers16020275.


New gene signature from the dominant infiltration immune cell type in osteosarcoma predicts overall survival.

Gong L, Sun X, Jia M Sci Rep. 2023; 13(1):18271.

PMID: 37880378 PMC: 10600156. DOI: 10.1038/s41598-023-45566-6.


Survival outcomes and surgical morbidity based on surgical approach to pulmonary metastasectomy in pediatric, adolescent and young adult patients with osteosarcoma.

Kuo C, Malvar J, Chi Y, Kim E, Shah R, Navid F Cancer Med. 2023; 12(20):20231-20241.

PMID: 37800658 PMC: 10652329. DOI: 10.1002/cam4.6491.


Solitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group.

Mettmann V, Baumhoer D, Bielack S, Blattmann C, Friedel G, von Kalle T Cancer Med. 2023; 12(17):18219-18234.

PMID: 37548393 PMC: 10524021. DOI: 10.1002/cam4.6409.